Clinical Trial Update: Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a lymphocyte-depleting nonmyeloablative preparative regimen followed by autologous lymphocyte infusion, a peptide vaccine with Montanid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Autologous lymphocyte infusion (autologous lymphocyte infusion)
• Interleukin-2 (interleukin-2)
• Lymphocyte-depleting nonmyeloablative preparative chemotherapy
• Montanide ISA-51 (adjuvant Montanide ISA-51)
• peptide vaccine

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED